Semaglutide Impurity: What the Evidence Says About Quality and Safety

What the MHRA's counterfeit warnings tell us about impurity in practice

The clearest evidence that semaglutide impurity is a real-world risk, not a theoretical one, comes from the MHRA's own enforcement record. Starting with a major public warning in October 2023, the regulator documented counterfeit pens labelled as semaglutide or liraglutide products being sold without a prescription through social media channels and unlicensed online sellers. Some of those pens contained insulin, a drug with an entirely different mechanism and a narrow therapeutic window that can cause life-threatening hypoglycaemia in people without diabetes. Others contained concentrations of active substance that bore no relation to what was printed on the label. In 2025, enforcement escalated further: around 20 million doses of illegally traded weight-loss medicines, estimated at roughly £45 million street value, were seized, and the first known UK site manufacturing counterfeit tirzepatide pens was raided. None of those products had passed any impurity testing. The MHRA's Yellow Card scheme remains the mechanism for reporting both adverse reactions and suspect sellers, worth bookmarking whether you're on treatment or researching it.

For licensed Wegovy, the picture is different. Novo Nordisk's manufacturing process is subject to EU and MHRA Good Manufacturing Practice inspections, and every batch must meet the impurity specifications in the approved Summary of Product Characteristics before release. The semaglutide overview page covers what the licensed product contains and how it works, which is useful context alongside this safety discussion.

How degradation creates impurity even in genuine semaglutide

Impurity doesn't only arise from counterfeiting. Even an authentic, correctly labelled Wegovy pen can develop chemical degradation products if it is stored incorrectly. Semaglutide is a peptide (a chain of amino acids) and like all peptides it is sensitive to heat and, to a lesser extent, light. The approved storage conditions require refrigeration at 2–8°C prior to first use; once in use, the pen may be kept at room temperature for a defined period, but the exact window is specified in the Patient Information Leaflet and the Mounjaro and Wegovy SmPCs on the eMC, not in promotional copy. Leaving a pen on a sunny windowsill, or in a bag in a hot car boot, accelerates breakdown of the active molecule into degradation products, compounds that have not been tested for safety or efficacy in humans. The practical upshot: if a pen has been outside recommended temperature range for an unknown period (bought from an unverified seller and posted in a jiffy bag, for instance) there is no way to know its impurity profile from appearance alone. A cloudy or discoloured solution is one signal, but many degradation products are colourless. This is also worth keeping in mind around holidays or busy periods; if your delivery is sitting on a doorstep in July heat or delayed over a bank holiday weekend, checking storage conditions with your prescriber before using a pen is a sensible call.

What 'purity specifications' actually mean for a licensed Wegovy pen

When a medicines regulator approves a product like Wegovy, it approves not just the active ingredient and its dose but also the acceptable limits for every identified impurity and for total unspecified impurities. These are set based on toxicological data, essentially, the concentration at which a given impurity would need to be present before it poses a plausible health risk. Novo Nordisk submits batch-testing data demonstrating compliance with these specifications to the MHRA; the regulator can also conduct its own testing. This is the Quality part of the pharmaceutical Quality, Safety and Efficacy triad that underpins UK licensing. The MHRA Drug Safety Updates index is where post-approval safety signals (including any impurity-related findings) would be communicated publicly. No impurity-related safety communication has been issued for licensed Wegovy batches in the UK supply chain as of summer 2026. For anyone who wants to explore whether Wegovy is appropriate for their situation, understanding the 0.25mg starting dose and the clinical pathway from there is a good starting point, and details on how the semaglutide 2mg dose is used alongside guidance on the semaglutide 3mg stage help complete the picture of the full titration journey, the weight-loss treatments overview maps out the full picture.

The practical safety question: how to avoid impurity exposure

The most effective way to avoid semaglutide impurity exposure is straightforward, if not always the cheapest option: obtain treatment only through a pharmacy that you can verify on the GPhC register, following a proper clinical assessment. A GPhC-registered pharmacy sources from the authorised supply chain, is subject to inspection, and does not sell prescription medicines without a prescription. Red flags that suggest an unverified source include pens offered without a clinical consultation, prices dramatically below the market range, or seller accounts on social media platforms with no verifiable registration. If you already hold a prescription and want to understand more about what the clinical pathway involves, how Wegovy is prescribed and supplied in the UK explains the steps. Our prescribers at nume source exclusively through licensed UK channels and review every order clinically before dispatch. If you have questions about a specific pen or supply situation, getting in touch with our team is the most direct route. When you're ready to take the next step, speaking to our prescribers begins with a free consultation.